Inventaire - your friends and communities are your best library

Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial

published in: Vaccine

date of publication: 2011-08-09

main subject: placebo, vaccine, placebo-controlled trial

Cites articles 21

Date

Title

Authors

2011-01-28

Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age
2010-11-01

Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults.

Sharon E Frey
2010-03-17

Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons

Harry L Keyserling, Lisa A Jackson
2009-10-29

Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccine (TIV) among persons > or =65 years old
2009-09-01

Comparative efficacy of inactivated and live attenuated influenza vaccines

Arnold S. Monto, Suzanne E Ohmit
2009-01-17

Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example

Veronika Wertzova, Bruce L. Innis
2009-01-01

Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.

Yan Li, Nathalie Bastien, Hugues Charest, Gaston De Serres, Danuta M. Skowronski, Martin Petric, Kevin Fonseca, Trijntje L Kwindt, Tracy Chan
2008-12-01

Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses

Wendy A Keitel, Alexander I Klimov, Nancy Cox
2008-08-20

Influence of prior influenza vaccination on antibody and B-cell responses

Harry B. Greenberg, Cornelia L Dekker, Ann Arvin
2007-04-01

Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial

Frederick G Hayden
2006-03-28

Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.
2006-10-16

Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada.
2005-09-19

Antibody response to influenza vaccination in the elderly: a quantitative review

Cécile Viboud, Lone Simonsen
2004-11-01

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

Eduardo L. Franco, Bruce L. Innis, Cosette M Wheeler, Wim Quint
2000-06-01

Symptomatic pericarditis after influenza vaccination: report of two cases
1996-10-01

Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults
1996-06-01

Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults.

Robert B Belshe
1996-10-01

Effects of repeated annual influenza vaccination on vaccine sero-response in young and elderly adults

Ab Osterhaus
1995-06-01

Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well tolerated and induce protective immune responses in healthy adults.

Robert B Belshe
1989-08-01

Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs

Robert G. Webster
1989-07-01

Influenza A (H1N1) vaccine efficacy in animal models is influenced by two amino acid substitutions in the hemagglutinin molecule

Article - wd:Q84747835

Welcome to Inventaire

the library of your friends and communities

learn more